Cargando…

Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer

As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbasi, Amin, Heydari, Sahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036304/
https://www.ncbi.nlm.nih.gov/pubmed/29991989
http://dx.doi.org/10.4081/ejtm.2018.7423
_version_ 1783338141264904192
author Abbasi, Amin
Heydari, Sahar
author_facet Abbasi, Amin
Heydari, Sahar
author_sort Abbasi, Amin
collection PubMed
description As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.
format Online
Article
Text
id pubmed-6036304
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-60363042018-07-10 Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer Abbasi, Amin Heydari, Sahar Eur J Transl Myol Article As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer. PAGEPress Publications, Pavia, Italy 2018-06-04 /pmc/articles/PMC6036304/ /pubmed/29991989 http://dx.doi.org/10.4081/ejtm.2018.7423 Text en http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Abbasi, Amin
Heydari, Sahar
Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title_full Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title_fullStr Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title_full_unstemmed Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title_short Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer
title_sort studying the expression rate and methylation of reprimo gene in the blood of patients suffering from gastric cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036304/
https://www.ncbi.nlm.nih.gov/pubmed/29991989
http://dx.doi.org/10.4081/ejtm.2018.7423
work_keys_str_mv AT abbasiamin studyingtheexpressionrateandmethylationofreprimogeneinthebloodofpatientssufferingfromgastriccancer
AT heydarisahar studyingtheexpressionrateandmethylationofreprimogeneinthebloodofpatientssufferingfromgastriccancer